Request to Join
has invited you to join this group
Dr. Rutherford is the Salvatore Pablo Lucia Professor of Epidemiology, Preventive Medicine, Pediatrics and History; Head of the Division of Infectious Disease Epidemiology and Vice Chair of the Department of Epidemiology and Biostatistics at the University of California, San Francisco. He directs UCSF’s residency program in General Preventive Medicine and Public Health and helped create the highly innovative joint internal medicine-preventive medicine residency program in partnership with the Kaiser Permanente Medical Center San Francisco. He also directs the Prevention and Public Health Group within UCSF’s program in Global Health Sciences. Educated at Stanford University and Duke University School of Medicine, he is board certified in pediatrics and general preventive medicine and public health. He has worked primarily in public health, with an emphasis on the epidemiology and control of communicable diseases, both domestically and internationally. He has held a number of positions in public health agencies, including having served as State Health Officer and State Epidemiologist for California, Director of the AIDS Office for the San Francisco Department of Public Health, Director of Immunizations for the New York City Department of Health and an Epidemic Intelligence Service Officer at CDC. He has been in academic medicine and public health since 1995, where his interests have largely focused the epidemiology and control of infectious diseases of public health importance, and more specifically on HIV infection in low- and middle-income countries. He has a special interest in meta-analysis and has served as the Coordinating Editor of the Cochrane Collaboration’s HIV/AIDS Group. He is Principal Investigator of a group of cooperative agreements with CDC to support its Center for Global Health and works on projects in Brazil, Croatia, the Dominican Republic, the Eastern Caribbean, Ghana, Haiti, Iran, Kenya, Mozambique, Namibia, Rwanda, South Africa, Tanzania, Uganda, Ukraine, Vietnam and Zambia. Dr. Rutherford serves as an advisor to the World Health Organization, the United Nations Joint Programme on HIV and AIDS and the Global Fund to Fight AIDS, Tuberculosis and Malaria, is the past chair the American Academy of Pediatrics Section on Epidemiology and was the first Chair of the Department of Veterans Affairs Research Advisory Council. He has also served on the Institute of Medicine’s Board on the Health of Select Populations and has chaired Institute of Medicine committees on traumatic brain injury in Iraq and the readjustment needs of military personnel and reservists returning from Iraq and Afghanistan and their families.
Education and current employment: MD 1987 (University of Copenhagen), specialized in internalmedicine, infectious diseases and tropicalmedicine; professorininfectious disease epidemiology and in viral diseases 2005 and 2007, resp. (University ofCopenhagen). Since 1998 Director of CHIP, Centre for Health and Infectious Disease Research. Since 2015, center leader of National Research Foundation Center of Excellence PERSIMUNE. Research achievements: Has 20+ years of expertise in leading large internationalresearch related to infectious complications in HIV+ persons and transplant recipients funded by the European Commission (EuroSIDA in EuroCoord), the European Medicines Agency (D:A:D) and NIH (INSIGHT studies). Lead of the European‐funded networks and co‐founder of the global infectious disease research network INSIGHT. Founded MATCH in 2010 to monitor viral infections in transplant patients at Rigshospitalet, now by a grant from the Danish National Research Foundation turned into a research platform across Rigshospitalet to identify factors predicting the risk of infectious complication in immune deficient patients. Coordinating activities among 250+ international institutions documents his ability to manage large data mergers and perform hypotheses‐driven and ‐generating research. Recent years he focused on establishing evidence for the optimal initiation of antiretroviral therapy in HIV infected patients, investigating non‐AIDS defining malignancies and inflammation mediated organ disease, especially focused on kidney, liver and cardiovascular diseases; viral diseases in transplant recipients and the impact of changing mutations of influenza viruses in the global epidemic. His team is Global Centre of Excellence in Health and has status of ‘Collaborative Centre for HIV and Viral Hepatitis’ by the WHO. Supervised 19 PhDs and 6DMScs and has ongoing supervision for 12PhDs and 4DMScs.
Dr Alison Rodger is a clinical academic in infectious diseases and HIV at University College London. Her main research interests are in HIV transmission, testing and prevention. She was the lead author on the PARTNER study which reported on HIV transmission risk in the context of suppressive ART, and she is the PI on a programme of work investigating the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among gay men in the UK.
Ronald Swanstrom, Ph.D., Charles Postelle Distinguished Professor of Biochemistry and Biophysics, Director UNC Center For AIDS Research, University of North Carolina at Chapel Hill
Dr Xavier Anglaret (MD, PhD) is a physician, specialist in Internal Medicine and Clinical Research. He is the Director of the team “Infectious Diseases in Lower Income Countries” (IDLIC) at the Inserm 1219 research center of the university of Bordeaux in France. He also co-leads with Thérèse N’Dri-Yoman the PAC-CI/ANRS-Inserm research team in Abidjan, Côte d’Ivoire. His main research interest is HIV infection and associated diseases in sub-Saharan Africa. He was the principal investigator of the Cotrimo-CI ANRS 059 trial that demonstrated the efficacy of cotrimoxazole prophylaxis in reducing severe morbidity in HIV-infected adults with high CD4 counts in West Africa (Lancet 1999). He was also the co-principal investigator, together with Serge Eholie, of the TEMPRANO ANRS 12136 trial, a large trial that showed that initiating antiretroviral therapy (ART) at high CD4 counts reduced the risk of early severe morbidity in low resource contexts where tuberculosis and other bacterial diseases were highly prevalent (N Eng J Med 2015). In 2015, these strong individual benefits demonstrated in TEMPRANO, in addition to individual benefits demonstrated in another trial named START and to population benefits consisting of preventing HIV transmission demonstrated in a third trial named HPTN052, justified the recommendation by WHO that HIV-infected persons should initiate ART regardless of CD4 count.